Cyclosporine for the Treatment of HTLV-1-Induced HAM/TSP An Experience from a Case Report

HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) remains a challenging disease. Treatment options are scarce, and their safety and efficacy are currently a matter of concern. We present a case report describing our experience using cyclosporine in a patient with early HAM/TSP who...

Full description

Saved in:
Bibliographic Details
Published inMedicine (Baltimore) Vol. 94; no. 1; p. e382
Main Authors Sánchez-Montalvá, Adrián, Salvador, Fernando, Caballero, Estrella, Molina, Israel
Format Journal Article
LanguageEnglish
Published Wolters Kluwer Health 09.01.2015
Subjects
Clinical Case Report
Online AccessGet full text

Cover

More Information
Summary:HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) remains a challenging disease. Treatment options are scarce, and their safety and efficacy are currently a matter of concern. We present a case report describing our experience using cyclosporine in a patient with early HAM/TSP who started with a gait disturbance at Vall d’Hebron University Hospital (Barcelona) from August 2012 to October 2013. After 62 weeks of treatment, clinical improvement was observed and proviral load diminished. No safety concerns were observed. Cyclosporine seems to be effective in new-onset HAM/TSP or in chronic HAM/TSP that develops a relapse. However, the duration and safety profile of this steroid-sparing therapy remain unknown and should be further investigated.
ISSN:0025-7974
1536-5964
DOI:10.1097/MD.0000000000000382